Status:
WITHDRAWN
Reducing Port Access Pain and Clinic Wait Time: An Evaluation of EMLA Cream Versus nüm™ Vapocoolant Spray
Lead Sponsor:
Marianne Hutti
Collaborating Sponsors:
Bimeco Group
Conditions:
Pediatric Cancer
Eligibility:
All Genders
4-18 years
Phase:
PHASE4
Brief Summary
The goal of this clinical trial is to compare a sterile vapocoolant spray to EMLA cream in children with access ports. Participants will receive either the spray or cream prior to port access and rat...
Eligibility Criteria
Inclusion
- English-speaking
- Present appointment is for drawing blood, receiving intravenous antibiotics, blood products, or chemotherapy
- EMLA cream has (standard of care) or has not (vapocoolant) been applied to the port site prior to the appointment
- Previous allergic reaction or skin irritation due to EMLA
- Quick access to the child's port is needed for drawing blood, or giving treatments, blood products, or drugs such as chemotherapy
Exclusion
- Child has a legal guardian or non-parent family member as the only adult with them for the visit.
- Children less than 4 years of age
- Children with altered mental status
- History of traumatic brain injury, developmental delay or autism
- Child is nonverbal
- Present appointment is for drawing blood, receiving intravenous antibiotics, blood products, or chemotherapy, and child and parents prefer to wait for EMLA cream to take effect.
Key Trial Info
Start Date :
December 23 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 20 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06023368
Start Date
December 23 2023
End Date
June 20 2024
Last Update
November 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kentucky DanceBlue Pediatric Hematology/oncology clinic
Lexington, Kentucky, United States, 40506